Gabather
0.578
SEK
-1.37 %
GABA
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
1 following
-1.37%
+3.58%
-12.42%
-63.18%
-57.43%
-74.35%
-85.54%
-86.2%
-96.37%
www.gabather.com
Gabather is a pharmaceutical company. Today, there is a business focus on developing drug candidates for the treatment of nerve diseases. Particular focus is on the stimulation of gamma-aminobutyric acid, which is the main inhibitory neurotransmitter in the brain. The drug candidates are today patented on a global level. Gabather was established in 2014 and is headquartered in Malmö.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
GABA
Daily low / high price
0.578 / 0.586
SEK
Market cap
13.71M SEK
Turnover
1.31K SEK
Volume
2.3K
Financial calendar
Interim report
2024-11-28
Annual report
2025-02-27
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Avanza Pension | 12.6 % | 12.6 % |
| Nordnet Pension | 2.2 % | 2.2 % |
| Investment Aktiebolaget Balticum | 2.1 % | 2.1 % |
| Thomas Nilsson | 1.6 % | 1.6 % |
| Jorgen Jutholm | 1.5 % | 1.5 % |
| Handelsbanken Liv Försäkringsaktiebolag | 1.3 % | 1.3 % |
| Magnus Esselmark | 1.3 % | 1.3 % |
| Kristian Falk | 1.2 % | 1.2 % |
| Anders Asplund | 1.1 % | 1.1 % |
| Anica Kabbenas | 1.1 % | 1.1 % |
ShowingAll content types
Kontrollbalansräkning utvisar att aktiekapitalet i Gabather AB är intakt
Gabather AB: Gabather publicerar delårsrapport 1 januari - 30 juni 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools